Renaissance Technologies LLC Sells 146,150 Shares of Kodiak Sciences Inc. (NASDAQ:KOD)

Renaissance Technologies LLC trimmed its position in shares of Kodiak Sciences Inc. (NASDAQ:KOD - Free Report) by 24.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 461,600 shares of the company's stock after selling 146,150 shares during the quarter. Renaissance Technologies LLC owned approximately 0.88% of Kodiak Sciences worth $4,593,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also made changes to their positions in the company. State Street Corp increased its position in Kodiak Sciences by 1.8% during the third quarter. State Street Corp now owns 816,634 shares of the company's stock worth $2,131,000 after buying an additional 14,711 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Kodiak Sciences by 1.7% in the 3rd quarter. Geode Capital Management LLC now owns 768,740 shares of the company's stock valued at $2,007,000 after purchasing an additional 12,783 shares during the period. Invesco Ltd. increased its stake in Kodiak Sciences by 545.7% during the fourth quarter. Invesco Ltd. now owns 519,010 shares of the company's stock valued at $5,164,000 after acquiring an additional 438,635 shares during the period. Peapod Lane Capital LLC bought a new stake in shares of Kodiak Sciences during the fourth quarter valued at approximately $1,660,000. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Kodiak Sciences by 194.9% during the 4th quarter. JPMorgan Chase & Co. now owns 131,646 shares of the company's stock worth $1,310,000 after acquiring an additional 86,998 shares during the period. Institutional investors own 89.06% of the company's stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a "neutral" rating and issued a $3.00 target price on shares of Kodiak Sciences in a report on Monday, March 31st.

Kodiak Sciences Price Performance

Shares of KOD traded down $0.08 on Friday, hitting $4.11. The company's stock had a trading volume of 252,155 shares, compared to its average volume of 342,933. The company has a market capitalization of $216.79 million, a PE ratio of -1.13 and a beta of 2.40. Kodiak Sciences Inc. has a fifty-two week low of $1.92 and a fifty-two week high of $11.60. The company has a 50 day moving average price of $3.27 and a 200 day moving average price of $5.40.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) last announced its earnings results on Thursday, March 27th. The company reported ($0.84) EPS for the quarter, topping the consensus estimate of ($0.90) by $0.06. On average, equities analysts forecast that Kodiak Sciences Inc. will post -3.45 EPS for the current year.

Kodiak Sciences Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.